Rock Springs Capital Management LP Puma Biotechnology, Inc. Transaction History

Rock Springs Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $3.82 Million - $6.3 Million	-587,400 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $463,750 - $681,050	53,000 Added 9.92%	587,400 $6.32 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $939,720 - $2.73 Million	76,400 Added 16.68%	534,400 $6.79 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $31,944 - $65,165	1,538 Added 0.34%	458,000 $17.8 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $624,939 - $1.45 Million	-31,138 Reduced 6.39%	456,462 $9.29 Million
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $486,160 - $706,230	11,800 Added 2.48%	487,600 $22.4 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $3.04 Million - $4.29 Million	62,900 Added 15.23%	475,800 $28.1 Million
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $2.35 Million - $3.91 Million	39,400 Added 10.55%	412,900 $28.1 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $4.08 Million - $5.76 Million	43,500 Added 13.18%	373,500 $36.9 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $23.8 Million - $39.5 Million	330,000	330,000 $39.5 Million

100

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $135M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.